Source: Eur Respir J 2013; 42: 288-290
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Giovanni Sotgiu, Rosella Centis, Lia D'Ambrosio, Antonio Spanevello, Giovanni Battista Migliori, on behalf of the International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290

Member's Comments

No comment yet.

Related content which might interest you: Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2013; 42: 169-179 Year: 2013 Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Microscopic observation drug susceptibility assay for the diagnosis of TB and MDR-TB in HIV-infected patients: a systematic review and meta-analysis Source: Eur Respir J 2014; 44: 973-984 Year: 2014 Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study Source: Eur Respir J 2015; 46: 1205-1207 Year: 2015 Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence Source: Eur Respir J 2016; 47: 394-402 Year: 2016 Is multidrug-resistant TB more common in children? An analysis of surveillance data Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios Source: Eur Respir J 2015; 45: 25-29 Year: 2015 Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017 Year: 2017 Bedaquiline containing regimens for the treatment of multi- and extensively drug-resistant tuberculosis at the programmatic level in Belarus. Prospective cohort study. Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019 A study of prescription of second line drugs in chronic tuberculosis patients before confirmation of multi drug resistance bacteriologically Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016 Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017 Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Evaluation of efficacy and safety of linezolid for the treatment of drug-resistant tuberculosis: case series report of 12 patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Multi-drug resistant tuberculosis: a retrospective analysis of cases over 10 years in a low incidence setting Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 First data about the efficacy of moxifloxacin in the treatment of pulmonary tuberculosis – a prospective, randomised study versus INH Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations Year: 2003 Clinical outcomes of patients with drug-resistant and extensively drug-resistant tuberculosis in Europe Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008